Evaluation of a newly developed office-based stool test for detecting XXXX : an extensive pilot study.

@entity1 @entity1133 @entity3621 @entity1534 @entity13639
BACKGROUND/AIMS: Several strategies have been used to detect @entity1534 (Hp) infection along two lines: 1) direct detection of the bacteria, and 2) detection of antigen-antibody assay against Hp. The non-invasive methods include ELISA test of serum, salivary and urine, @entity1133 breath test, and detection of Hp antigen in stool. The latter method (HpSA) has been proven reliable and better than the ELISA test, for it can detect current @entity13639 and is suitable for post-treatment follow-up. Now, a new commercial kit, ImmunoCard STAT HpSA (Meridian Bioscience Europe) has been developed to detect stool Hp antigen. It is simpler and less time-consuming than HpSA. The aim was to examine whether ImmunoCard STAT HpSA is qualified for diagnosis of @entity13639 . METHODOLOGY: 253 @entity1 (163 @entity1 , 90 @entity1 , mean age: 53.3 +/- 13.9 y/o, range: 19-89 y/o) were enrolled in this study. All of them had undergone gastroendoscopy and @entity1133 breath test. 207 @entity1 were diagnosed with peptic ulcer and 46 with @entity3621 . Stool samples were collected within 3 days of their visit for gastroendoscopy and were sent for the Immunocard test. RESULTS: 118 @entity1 were diagnosed with @entity13639 and of these, 113 were interpreted as positive by means of the Immunocard test. Among the other 135 @entity1 without @entity13639 , 123 were interpreted as negative by means of the Immunocard test. Sensitivity and specificity were 95.8% and 91.1%, and positive and negative predictive values were 90.4% and 96.1%. CONCLUSIONS: The ImmunoCard STAT HpSA had high sensitivity, and specificity and could be used for mass screening. We concluded that it is a rapid, simple, cheap, reliable, and non-invasive strategy to detect current @entity13639 and can be used in post-Hp eradication follow-up in Taiwan.
